Preventative Effect of Mebendazole against Malignancies in Neurofibromatosis 1. (2020)

Peer-Reviewed Study · Verena Staedtke; Tyler Gray-Bethke; Gregory J Riggins et al. · July 8, 2020

Verena Staedtke et al., 2020-07-08: Staedtke et al. test mebendazole as chemoprevention in an NF1 mouse model, reporting delayed malignancy, longer survival and lower pERK, with further benefit when combined with celecoxib.

The daily MBZ treatment of NPcis mice dosed at 195 mg/kg daily, initiated 60 days after birth, substantially delayed the formation of solid malignancies and increased median survival (p < 0.0001).

Verena Staedtke et al., 2020-07-08: Staedtke et al. test mebendazole as chemoprevention in an NF1 mouse model, reporting delayed malignancy, longer survival and lower pERK, with further benefit when combined with celecoxib. Study type: cisNf1+/-;Tp53+/- (NPcis) mouse chemoprevention model plus MPNST cells. N: not stated in the abstract; several diet groups. Country: USA (Johns Hopkins). Dose: 175, 195, 215 or 250 mg/kg mebendazole polymorph C in feed from day 60; 195 mg/kg was the highest long-term tolerated dose. Funder: US NIH K08 CA230179. Declared conflicts: 'A patent on MBZ has been filed by JHU, with R-Y.B, V.S. and G.J.R. listed as inventors.' Comparator: placebo diet, and celecoxib 1000 ppm alone and in combination. Study type: animal.